Drug Profile
Research programme: rheumatoid arthritis therapy - GEMACBIO
Alternative Names: GEM RA; Rheumatoid arthritis therapy research programme - GEMACBIOLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GEMACBIO
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatic-disorders in France
- 11 Aug 2005 Preclinical trials in Rheumatic disorders in France (unspecified route)